Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys
Ca. Paronis et al., Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys, PSYCHOPHAR, 156(4), 2001, pp. 461-468
Rationale: The role of different types of GABAA receptors in mediating anti
conflict and response rate-decreasing effects of benzodiazepines in primate
species is not known. Objective: To examine the behavioral effects of the
benzodiazepine-site, GABAA agonists zolpidem, zaleplon, and midazolam in th
e presence of two antagonists, flumazenil and beta -carboline-3-carboxylate
-t-butyl ester (beta -CCt) in squirrel monkeys. Methods: Two schedules of o
perant responding were used: (1) a multiple fixed-ratio (FR) schedule of fo
od presentation involving punished and nonpunished behavior, and (2) an FR
schedule of stimulus shock-termination. Results: Midazolam (0.03-1.0 mg/kg)
, zolpidem (0.1-3.0 mg/kg), and zaleplon (0.1-3.0 mg/kg) increased rates of
punished responding and decreased rates of nonpunished responding under th
e multiple schedule. Pretreatment with flumazenil (0.3-1.0 mg/kg) antagoniz
ed the anticonflict and response rate-decreasing effects of all three agoni
sts. Pretreatment with beta -CCt (3-10 mg/kg) antagonized the anticonflict
and rate-decreasing effects of midazolam, as well as the rate-decreasing ef
fects of zolpidem and zaleplon. However, beta -CCt did not antagonize the a
nticonflict effects of zolpidem and zaleplon; instead, these effects of zol
pidem and zaleplon were apparently enhanced in the presence of beta -CCt. U
nder the schedule of stimulus shock-termination, both flumazenil and beta -
CCt antagonized zolpidem and zaleplon; however, the effects of beta -CCt we
re less consistent than the effects of flumazenil. Conclusion: In nonhuman
primates, different types of GABAA receptors may mediate the anticonflict a
nd the response rate-decreasing effects of the nonselective GABAA agonist m
idazolam and the selective GABA(A1) agonists zolpidem and zaleplon.